Pacira BioSciences Inc [PCRX] stock is trading at $26.98, up 2.20%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PCRX shares have gain 5.56% over the last week, with a monthly amount glided 4.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on January 30, 2025, when Truist upgraded its rating to a Hold and also boosted its price target to $25 from $8. Previously, Truist downgraded its rating to Sell on August 13, 2024, and dropped its price target to $8. On August 12, 2024, downgrade downgraded it’s rating to Sector Perform and revised its price target to $14 on the stock. Raymond James downgraded its rating to a Mkt Perform. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $11 on August 12, 2024. JP Morgan downgraded its rating to Underweight for this stock on August 12, 2024, and downed its price target to $10. In a note dated July 03, 2024, Barclays downgraded an Equal Weight rating on this stock and revised its target price from $38 to $25.
Pacira BioSciences Inc [PCRX] stock has fluctuated between $11.16 and $31.12 over the past year. Currently, Wall Street analysts expect the stock to reach $32.33 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $26.98 at the most recent close of the market. An investor can expect a potential return of 19.83% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
Pacira BioSciences Inc [NASDAQ:PCRX] reported sales of 702.77M for the trailing twelve months, which represents a growth of 1.08%. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.1%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.13 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Pacira BioSciences Inc’s Current Ratio is 2.41. Further, the Quick Ratio stands at 1.99, while the Cash Ratio is 0.9. Considering the valuation of this stock, the price to sales ratio is 1.78, the price to book ratio is 1.56.
Transactions by insiders
Recent insider trading involved RIKER LAUREN, Officer, that happened on Jun 04 ’25 when 5579.0 shares were purchased. Officer, WILLIAMS KRISTEN completed a deal on Jun 04 ’25 to buy 14376.0 shares. Meanwhile, Officer GAUGLER DARYL bought 500.0 shares on Mar 06 ’25.
